Full history for every metric is available with a Kvantra account
ReShape Lifesciences Inc. (RSLS)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 11 | 14 | 11 | 9 | 8 | 0 | 0 |
| Operating profit | $m | -3 | -12 | |||||
| Net profit | $m | -22 | -63 | -46 | -11 | -7 | -10 | -11 |
| EPS reported | $ | -4.75 | -29.87 | |||||
| Operating cashflow per share | $ | -1.73 | -1.36 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.73 | -1.36 | |||||
| Free cash flow | $m | -4 | -10 | |||||
| Net debt | $m | -5 | -8 | |||||
| Book value equity | $m | 4 | 7 | |||||
| Book value per share | $ | 1.74 | 1.04 | |||||
| Number of shares | m | 2.16 | 7.02 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 9.01 | 0.32 | |||||
| P/S LTM | x | 106.00 | 18.02 | |||||
| P/FCF LTM | x | -9.04 | -0.25 | |||||
| EV/EBITDA LTM | x | -10.58 | 21.01 | |||||
| EV/Sales LTM | x | 90.51 | -42.78 | |||||
| Earnings Yield LTM | % | -30.28% | -41.77% | |||||
| FCF Yield | % | -11.06% | -407.70% | |||||
| Quality | ||||||||
| ROE | % | -272.78% | -225.91% | |||||
| ROIC | % | -72.42% | -162.37% | |||||
| Operating margin | % | -859.22% | -9173.4% | |||||
| Gross margin | % | 68.43% | -796.25% | |||||
| FCF/Sales | % | -1172.6% | -7348.6% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -96.01% | -97.99% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -119.93 | -550.72 | |||||
| Net Debt/EBITDA | x | 1.81 | 29.80 | |||||
| EBIT/Net interest | x | -18.73 | -134.98 | |||||
| Net debt/market cap | % | -14.61% | -337.33% | |||||
| Net debt/Equity | x | -1.32 | -1.08 | |||||
| Gross debt/equity | x | 0.01 | 0.00 | |||||
Company overview
Founded in 2002 and based in San Clemente, California, ReShape Lifesciences Inc. operates as a medical device company dedicated to addressing obesity and metabolic diseases. The company's market extends throughout the United States, Australia, Europe, and globally. Its diverse product lineup features the Lap-Band System, a minimally invasive, long-term solution for severe obesity that offers an alternative to more extensive surgical interventions like gastric bypass or sleeve gastrectomy. Under development is the ReShape Vest system, an investigational, minimally invasive device that is laparoscopically implanted around the stomach to assist obese and morbidly obese patients in losing weight, without cutting or permanently removing parts of the stomach or bypassing any section of the gastrointestinal tract. ReShape also supports patients through the ReShapeCare virtual health coaching program, a telehealth service aimed at promoting healthy lifestyle adjustments for individuals undergoing medically supervised weight management. Additionally, the company is conducting preclinical development for ReShape Diabetes Bloc-Stim Neuromodulation, a technology intended for the treatment of type 2 diabetes mellitus. Among its offerings is the Obalon Balloon System, a swallowable capsule used to monitor and display the balloon's exact position during its placement. The company, initially incorporated as EnteroMedics Inc., changed its name to ReShape Lifesciences Inc. in 2017.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
ReShape Lifesciences Inc. (RSLS)
Founded in 2002 and based in San Clemente, California, ReShape Lifesciences Inc. operates as a medical device company dedicated to addressing obesity and metabolic diseases. The company's market extends throughout the United States, Australia, Europe, and globally. Its diverse product lineup features the Lap-Band System, a minimally invasive, long-term solution for severe obesity that offers an alternative to more extensive surgical interventions like gastric bypass or sleeve gastrectomy. Under development is the ReShape Vest system, an investigational, minimally invasive device that is laparoscopically implanted around the stomach to assist obese and morbidly obese patients in losing weight, without cutting or permanently removing parts of the stomach or bypassing any section of the gastrointestinal tract. ReShape also supports patients through the ReShapeCare virtual health coaching program, a telehealth service aimed at promoting healthy lifestyle adjustments for individuals undergoing medically supervised weight management. Additionally, the company is conducting preclinical development for ReShape Diabetes Bloc-Stim Neuromodulation, a technology intended for the treatment of type 2 diabetes mellitus. Among its offerings is the Obalon Balloon System, a swallowable capsule used to monitor and display the balloon's exact position during its placement. The company, initially incorporated as EnteroMedics Inc., changed its name to ReShape Lifesciences Inc. in 2017.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free